Download PDF

1. Company Snapshot

1.a. Company Description

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products.The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip.It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.


The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools.It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets.Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.

Show Full description

1.b. Last Insights on TWST

Breaking News: Twist Bioscience Corporation recently experienced a stock price gap down, opening at $49.90 on Friday, down from the previous close of $52.49. The company's shares last traded at $49.73 with a volume of 213406 shares. Several brokerages have issued reports on TWST, with varying ratings. Unfortunately, no information on recent earnings release is available. Analysts from TD have issued reports, however, specific recommendations to buy, hold or sell are not clear. Other brokerages have also weighed in on the company.

1.c. Company Highlights

2. Twist Bioscience's Q1 Fiscal 2026 Earnings: A Strong Start to the Year

Twist Bioscience Corporation reported a robust fiscal 2026 first quarter, with revenue increasing to $103.7 million, representing a 17% year-over-year growth and 5% sequential growth. The company's gross margin was 52%, a four-margin point increase over 2025, driven by revenue growth and process improvements. The earnings per share (EPS) came in at -$0.5, slightly worse than the estimated -$0.48. The revenue growth was driven by a 27% year-over-year increase in DNA synthesis and protein solutions revenue to $51.1 million, and a growth in NGS applications revenue to $52.6 million.

Publication Date: Feb -08

📋 Highlights
  • Revenue Growth:: Q1 revenue rose 17% YoY to $103.7M, with 5% sequential growth, driven by DNA synthesis (+27% to $51.1M) and therapeutics (+39% to $37.2M).
  • Gross Margin Expansion:: Gross margin hit 52%, up 400 bps YoY, with Q2 guidance above 52% and full-year margin improvement expected despite growth investments.
  • Adjusted EBITDA Progress:: Loss narrowed to $13.4M, an $2.8M improvement YoY, with confidence in achieving breakeven in 2026 despite $86.9M in operating expenses.
  • Regional Momentum:: EMEA revenue surged 36% YoY, Americas grew 9%, and AI-driven orders reached $25M in FY2025, reflecting durable demand in drug discovery.
  • Strategic Investments:: $435–440M 2026 revenue guidance (16% growth midpoint) backed by hiring, digital infrastructure (e.g., e-commerce for NGS), and supply chain excellence.

Segment Performance

The company's therapeutics revenue grew 39% year-over-year to $37.2 million, while diagnostics revenue remained stable at $35.3 million. Geographically, Americas revenue grew 9% year-over-year, EMEA revenue rose 36%, and APAC revenue increased slightly. The growth in DNA synthesis and protein solutions revenue was driven by AI, with over 50,000 genes manufactured for data characterization, and the demand for AI-driven drug discovery is seen as durable.

Guidance and Outlook

Twist Bioscience expects total revenue of $435 million to $440 million for fiscal 2026, with a growth of approximately 16% at the midpoint. The company remains confident in reaching adjusted EBITDA breakeven for 2026. The guidance was raised by more than the fiscal 1Q 2026 beat, driven by confidence across the board, with growth coming from DNA synthesis and NGS. Gross margin expectations for the full year are above 52%, with continued improvements throughout the year.

Valuation and Metrics

With a P/S Ratio of 7.71 and an EV/EBITDA of -49.47, the market is pricing in significant growth expectations. The company's commitment to adjusted EBITDA breakeven by Q4 this year, driven by a repeatable, scalable model, innovative technology, and operational rigor, is expected to translate to improving financial performance. Analysts estimate next year's revenue growth at 15.5%, indicating a sustained growth trajectory.

Investment Strategy

The company has made targeted investments to drive growth, including in commercial teams and infrastructure, while maintaining its focus on core financial priorities. Strategic investments were made in hiring sales and commercial people, and transient investments in digital infrastructure, such as launching an e-commerce platform for NGS applications. The company plans to host an investor day in May to provide a deeper look at its customers, product roadmap, market expansion opportunities, and financial frameworks.

3. NewsRoom

Card image cap

Twist Bioscience (NASDAQ:TWST) Shares Gap Down – What’s Next?

Feb -22

Source: defenseworld.net

Card image cap

Twist Bioscience Corporation (TWST) Shareholder/Analyst Call Transcript

Feb -18

Source: seekingalpha.com

Card image cap

Cathie Wood Bets Big on Semiconductors, Adds Broadcom and AMD

Feb -18

Source: gurufocus.com

Card image cap

Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement

Feb -17

Source: businesswire.com

Card image cap

Biotech Beat Nvidia in 2025. Can It Do It Again?

Feb -11

Source: fool.com

Card image cap

Twist Bioscience Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes

Feb -10

Source: businesswire.com

Card image cap

Twist Bioscience: Liquid Biopsy And AI Tailwinds

Feb -10

Source: seekingalpha.com

Card image cap

These Analysts Increase Their Forecasts On Twist Bioscience After Q1 Results

Feb -03

Source: benzinga.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (14.97%)

6. Segments

Next Generation Sequencing Tools

Expected Growth: 15%

Twist Bioscience's Next Generation Sequencing (NGS) tools are driven by increasing adoption in precision medicine, liquid biopsy, and gene therapy. Growing demand for genetic data, advancements in synthetic biology, and declining sequencing costs also contribute to the 15% growth. Additionally, Twist's unique silicon-based DNA synthesis technology and partnerships with industry leaders further accelerate growth.

Synthetic Genes

Expected Growth: 16%

Twist Bioscience's synthetic genes segment growth is driven by increasing demand for gene therapy and synthetic biology research, accelerated by the COVID-19 pandemic. The company's unique silicon-based DNA synthesis platform enables rapid, high-throughput gene synthesis, fueling growth in the genomics and biotech industries.

Antibody Discovery

Expected Growth: 14%

Twist Bioscience's Antibody Discovery segment growth is driven by increasing adoption of synthetic biology tools, rising demand for targeted therapies, and growing partnerships with biopharma companies. The 14% growth rate is also fueled by the company's expanding library of antibodies, improved discovery workflows, and increasing investments in research and development.

Oligo Pools

Expected Growth: 13%

Twist Bioscience's Oligo Pools growth is driven by increasing adoption in synthetic biology, gene editing, and NGS applications. Rising demand for precision medicine, gene therapy, and COVID-19 research fuels growth. Additionally, Twist's unique silicon-based DNA synthesis platform enables high-throughput, cost-effective, and high-quality oligo production, further accelerating market penetration.

DNA Libraries

Expected Growth: 12%

Twist Bioscience's DNA Libraries segment growth is driven by increasing adoption in synthetic biology, gene therapy, and precision medicine. Rising demand for novel therapeutics, advancements in gene editing technologies, and growing investments in biotech research and development are key contributors to this 12% growth.

7. Detailed Products

Synthetic DNA

Twist Bioscience's synthetic DNA products are designed to provide high-quality, custom-made DNA sequences for various applications, including gene synthesis, genome editing, and synthetic biology.

Gene Fragments

Twist Bioscience's gene fragments are high-quality, custom-made DNA sequences that can be used to build genes, pathways, and genomes.

Oligo Pools

Twist Bioscience's oligo pools are high-diversity, custom-made pools of DNA oligonucleotides that can be used for various applications, including CRISPR-Cas9 genome editing and gene regulation.

Target Enrichment

Twist Bioscience's target enrichment products are designed to selectively enrich for specific genomic regions of interest, enabling cost-effective and efficient sequencing.

Exome Enrichment

Twist Bioscience's exome enrichment products are designed to selectively enrich for protein-coding regions of the genome, enabling efficient and cost-effective exome sequencing.

8. Twist Bioscience Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

Twist Bioscience Corporation's proprietary DNA synthesis technology and high-quality gene synthesis products make it difficult for substitutes to emerge, reducing the threat of substitutes.

Bargaining Power Of Customers

While customers have some bargaining power due to the availability of alternative gene synthesis providers, Twist Bioscience Corporation's strong brand reputation and high-quality products mitigate this power.

Bargaining Power Of Suppliers

Twist Bioscience Corporation's vertical integration and in-house manufacturing capabilities reduce its dependence on suppliers, minimizing their bargaining power.

Threat Of New Entrants

While the gene synthesis market is growing, high barriers to entry, including significant capital expenditures and regulatory hurdles, make it challenging for new entrants to compete with Twist Bioscience Corporation.

Intensity Of Rivalry

The gene synthesis market is highly competitive, with several established players, including Twist Bioscience Corporation, competing for market share and customer loyalty.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 13.11%
Debt Cost 3.95%
Equity Weight 86.89%
Equity Cost 12.06%
WACC 11.00%
Leverage 15.09%

11. Quality Control: Twist Bioscience Corporation passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
LabCorp

A-Score: 5.4/10

Value: 4.6

Growth: 4.3

Quality: 5.4

Yield: 2.0

Momentum: 7.0

Volatility: 9.3

1-Year Total Return ->

View Full Report
Stock-Card
Medpace

A-Score: 5.0/10

Value: 1.3

Growth: 9.3

Quality: 7.9

Yield: 0.0

Momentum: 9.5

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Natera

A-Score: 4.7/10

Value: 4.0

Growth: 7.0

Quality: 3.6

Yield: 0.0

Momentum: 8.5

Volatility: 5.0

1-Year Total Return ->

View Full Report
Stock-Card
Waters

A-Score: 4.4/10

Value: 1.0

Growth: 5.2

Quality: 7.7

Yield: 0.0

Momentum: 6.0

Volatility: 6.3

1-Year Total Return ->

View Full Report
Stock-Card
Twist Bioscience

A-Score: 3.8/10

Value: 6.8

Growth: 7.1

Quality: 4.6

Yield: 0.0

Momentum: 2.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Charles River Laboratories

A-Score: 3.3/10

Value: 4.6

Growth: 4.1

Quality: 3.1

Yield: 0.0

Momentum: 3.5

Volatility: 4.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

48.59$

Current Price

48.59$

Potential

-0.00%

Expected Cash-Flows